title: [A Case of Heterochronic Cervical Esophageal Cancer with a Subcutaneous Abscess Showing a Complete Response to Chemoradiation Therapy].
abstract: We report a case of heterochronic cervical esophageal cancer with a subcutaneous abscess successfully treated using chemoradiation. A 68-year-old man underwent esophagectomy for middle thoracic esophageal cancer 13 years ago. In April 2015, upper gastrointestinal endoscopy revealed advanced residual cervical esophageal cancer. Enhanced CT showed a massive tumor with a subcutaneous abscess, and the tumor had invaded the left internal jugular vein and the 8th cervical spine. We firstly performed abscess drainage and administered antibiotics. After the inflammation decreased, we started chemora- diation. Chemotherapy consisted of 70mg/m / 2 cisplatin(day 1)and 700 mg/m2 5-FU(days 1-5)combined with almost 60 Gy radiotherapy(1.8 Gy/day, 5 days/week, days 1-49). We administered cisplatin and 5-FU only once because renal dys- function occurred. Consequently, we changed the regimen to weekly 100mg/m2 paclitaxel administration(day 1). After 2 months, a clinical complete response(CR)was obtained and we stopped chemotherapy. Eight months after chemotherapy cessation, the patient shows no sign of recurrence. These results suggest that chemoradiation is an effective treatment for cervical esophageal cancer with a subcutaneous abscess.
authors.affiliation: Dept. of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine.
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Nishiyama
authors.forename: Shigeru
authors.initials: S
authors.lastname: Takeda
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Kanekiyo
authors.forename: Michihisa
authors.initials: M
authors.lastname: Iida
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kitahara
authors.forename: Yukio
authors.initials: Y
authors.lastname: Tokumitsu
authors.forename: Shinobu
authors.initials: S
authors.lastname: Tomochika
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Tokuhisa
authors.forename: Kasuhiko
authors.initials: K
authors.lastname: Sakamoto
authors.forename: Nobuakl
authors.initials: N
authors.lastname: Suzuki
authors.forename: Tomio
authors.initials: T
authors.lastname: Ueno
authors.forename: Shigeru
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Shigefumi
authors.initials: S
authors.lastname: Yoshino
authors.forename: Shouichi
authors.initials: S
authors.lastname: Hazama
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nagano
mesh_terms: D000038:Abscess / Q000209:etiology*; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000150:complications / Q000628:therapy*; D016629:Esophagectomy; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000150:complications / Q000628:therapy*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil